LIGAND PHARMACEUTICALS (LGND) Stock Fundamental Analysis

NASDAQ:LGND • US53220K5048

183.98 USD
-2.34 (-1.26%)
At close: Feb 20, 2026
183.98 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Taking everything into account, LGND scores 6 out of 10 in our fundamental rating. LGND was compared to 193 industry peers in the Pharmaceuticals industry. LGND has an excellent profitability rating, but there are some minor concerns on its financial health. LGND is growing strongly while it is still valued neutral. This is a good combination! With these ratings, LGND could be worth investigating further for growth investing!.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year LGND was profitable.
  • LGND had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: LGND reported negative net income in multiple years.
  • LGND had a positive operating cash flow in each of the past 5 years.
LGND Yearly Net Income VS EBIT VS OCF VS FCFLGND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

  • With an excellent Return On Assets value of 3.29%, LGND belongs to the best of the industry, outperforming 82.72% of the companies in the same industry.
  • LGND has a Return On Equity of 5.11%. This is amongst the best in the industry. LGND outperforms 83.77% of its industry peers.
  • LGND has a better Return On Invested Capital (1.58%) than 79.06% of its industry peers.
  • LGND had an Average Return On Invested Capital over the past 3 years of 1.12%. This is significantly below the industry average of 12.64%.
  • The 3 year average ROIC (1.12%) for LGND is below the current ROIC(1.58%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.29%
ROE 5.11%
ROIC 1.58%
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
LGND Yearly ROA, ROE, ROICLGND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

1.3 Margins

  • LGND has a better Profit Margin (19.34%) than 90.58% of its industry peers.
  • LGND has a Operating Margin of 11.48%. This is amongst the best in the industry. LGND outperforms 84.82% of its industry peers.
  • LGND's Operating Margin has declined in the last couple of years.
  • The Gross Margin of LGND (94.27%) is better than 96.34% of its industry peers.
  • In the last couple of years the Gross Margin of LGND has remained more or less at the same level.
Industry RankSector Rank
OM 11.48%
PM (TTM) 19.34%
GM 94.27%
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
LGND Yearly Profit, Operating, Gross MarginsLGND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300 400 500

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so LGND is destroying value.
  • LGND has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, LGND has more shares outstanding
  • The debt/assets ratio for LGND is higher compared to a year ago.
LGND Yearly Shares OutstandingLGND Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
LGND Yearly Total Debt VS Total AssetsLGND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

  • LGND has an Altman-Z score of 5.55. This indicates that LGND is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of LGND (5.55) is better than 77.49% of its industry peers.
  • LGND has a debt to FCF ratio of 14.48. This is a negative value and a sign of low solvency as LGND would need 14.48 years to pay back of all of its debts.
  • LGND has a better Debt to FCF ratio (14.48) than 78.01% of its industry peers.
  • LGND has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
  • LGND has a worse Debt to Equity ratio (0.47) than 61.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 14.48
Altman-Z 5.55
ROIC/WACC0.17
WACC9.27%
LGND Yearly LT Debt VS Equity VS FCFLGND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 24.69 indicates that LGND has no problem at all paying its short term obligations.
  • LGND's Current ratio of 24.69 is amongst the best of the industry. LGND outperforms 94.24% of its industry peers.
  • A Quick Ratio of 24.30 indicates that LGND has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 24.30, LGND belongs to the top of the industry, outperforming 93.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 24.69
Quick Ratio 24.3
LGND Yearly Current Assets VS Current LiabilitesLGND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 25.26% over the past year.
  • Measured over the past years, LGND shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.44% on average per year.
  • LGND shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.83%.
  • Measured over the past years, LGND shows a small growth in Revenue. The Revenue has been growing by 6.80% on average per year.
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.28% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 20.13% on average over the next years. This is a very strong growth
EPS Next Y35.4%
EPS Next 2Y21.72%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue Next Year48.19%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LGND Yearly Revenue VS EstimatesLGND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
LGND Yearly EPS VS EstimatesLGND Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 25.24, the valuation of LGND can be described as expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 79.06% of the companies listed in the same industry.
  • LGND's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.99.
  • Based on the Price/Forward Earnings ratio of 21.75, the valuation of LGND can be described as rather expensive.
  • 76.96% of the companies in the same industry are more expensive than LGND, based on the Price/Forward Earnings ratio.
  • LGND is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 25.24
Fwd PE 21.75
LGND Price Earnings VS Forward Price EarningsLGND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 76.96% of the companies in the same industry are more expensive than LGND, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, LGND is valued a bit cheaper than 75.39% of the companies in the same industry.
Industry RankSector Rank
P/FCF 117.71
EV/EBITDA 46.37
LGND Per share dataLGND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of LGND may justify a higher PE ratio.
  • LGND's earnings are expected to grow with 19.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.71
PEG (5Y)1.88
EPS Next 2Y21.72%
EPS Next 3Y19.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • LGND does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LIGAND PHARMACEUTICALS

NASDAQ:LGND (2/20/2026, 8:00:01 PM)

After market: 183.98 0 (0%)

183.98

-2.34 (-1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners106.73%
Inst Owner Change-0.81%
Ins Owners1.62%
Ins Owner Change-1.19%
Market Cap3.62B
Revenue(TTM)251.23M
Net Income(TTM)48.58M
Analysts85.71
Price Target248.31 (34.97%)
Short Float %6.67%
Short Ratio5.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.83%
Min EPS beat(2)10.36%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)19.98%
Min EPS beat(4)4.63%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)37.45%
EPS beat(12)12
Avg EPS beat(12)53.58%
EPS beat(16)15
Avg EPS beat(16)61.91%
Revenue beat(2)2
Avg Revenue beat(2)25.66%
Min Revenue beat(2)6.44%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)18.43%
Min Revenue beat(4)6.44%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.31%
Revenue beat(12)11
Avg Revenue beat(12)12.65%
Revenue beat(16)14
Avg Revenue beat(16)16.25%
PT rev (1m)0%
PT rev (3m)32.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10.34%
EPS NY rev (1m)3.65%
EPS NY rev (3m)10.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.73%
Valuation
Industry RankSector Rank
PE 25.24
Fwd PE 21.75
P/S 14.41
P/FCF 117.71
P/OCF 113.45
P/B 3.81
P/tB 8.86
EV/EBITDA 46.37
EPS(TTM)7.29
EY3.96%
EPS(NY)8.46
Fwd EY4.6%
FCF(TTM)1.56
FCFY0.85%
OCF(TTM)1.62
OCFY0.88%
SpS12.77
BVpS48.28
TBVpS20.77
PEG (NY)0.71
PEG (5Y)1.88
Graham Number88.99
Profitability
Industry RankSector Rank
ROA 3.29%
ROE 5.11%
ROCE 1.99%
ROIC 1.58%
ROICexc 2.92%
ROICexgc 9.48%
OM 11.48%
PM (TTM) 19.34%
GM 94.27%
FCFM 12.24%
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
ROICexc(3y)1.91%
ROICexc(5y)2.67%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.87%
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 14.48
Debt/EBITDA 7.07
Cap/Depr 3.38%
Cap/Sales 0.46%
Interest Coverage 96.15
Cash Conversion 50.63%
Profit Quality 63.32%
Current Ratio 24.69
Quick Ratio 24.3
Altman-Z 5.55
F-Score5
WACC9.27%
ROIC/WACC0.17
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
EPS Next Y35.4%
EPS Next 2Y21.72%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
Revenue Next Year48.19%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%
EBIT growth 1Y64.02%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year674.52%
EBIT Next 3Y155.59%
EBIT Next 5Y79.19%
FCF growth 1Y-61.26%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-66.41%
OCF growth 3Y7.19%
OCF growth 5YN/A

LIGAND PHARMACEUTICALS / LGND FAQ

What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?

ChartMill assigns a fundamental rating of 6 / 10 to LGND.


What is the valuation status of LIGAND PHARMACEUTICALS (LGND) stock?

ChartMill assigns a valuation rating of 5 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.


How profitable is LIGAND PHARMACEUTICALS (LGND) stock?

LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 7 / 10.


What is the financial health of LIGAND PHARMACEUTICALS (LGND) stock?

The financial health rating of LIGAND PHARMACEUTICALS (LGND) is 6 / 10.